Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
LFCR
$7.56
$-0.21
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
Next Earnings
2026-01-11
Beta
0.592
Average Volume
161866
Market Cap
282839997
Last Dividend
0
CIK
0001005286
ISIN
US5147661046
CUSIP
CEO
Paul Josephs
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full Time Employees
524
IPO Date
1996-02-15
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Reaches Settlement | Philadelphia, Pennsylvania--(Newsfile Corp. - January 8, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. Current Lifecore Biomedical, Inc. (NASDAQ: LFCR) who have held shares since before October 7, 2020, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. | Newsfile Corp | 2026-01-08 16:38:00 |
| Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf | PHILADELPHIA, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. | Globe News Wire | 2026-01-02 09:05:13 |
| Lifecore Biomedical: The Turnaround Is Just Getting Started | Lifecore Biomedical (LFCR) has completed its turnaround, emerging as a pure-play US-based CDMO with a cleaned-up balance sheet and high operational leverage. LFCR's new capacity is underutilized but already contracted, with management guiding revenues to rise from $128M to $178–205M and EBITDA margins to expand from 15% to over 25%. Alcon's take-or-pay contract and a major commercial site transfer underpin the revenue ramp, while macro tailwinds and supply chain onshoring boost demand. | Seeking Alpha | 2026-01-01 08:50:51 |
| Notice to Long-Term Shareholders of Lifecore Biomedical, Inc. (LFCR): Grabar Law Office Investigates Claims on Your Behalf as Securities Fraud Class Action Reaches Settlement | Philadelphia, Pennsylvania--(Newsfile Corp. - December 30, 2025) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. Current Lifecore Biomedical, Inc. (NASDAQ: LFCR) who have held shares since before October 7, 2020 can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. | Newsfile Corp | 2025-12-30 15:57:50 |
| HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS | Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary duties to shareholders. | PRNewsWire | 2025-12-24 12:30:00 |
| Lifecore Biomedical to be Added to Nasdaq Biotech Index | CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has been notified by Nasdaq that the company's stock is expected to be added to the Nasdaq Biotech Index (NASDAQ: NBI) as part of the annual reconstitution of the 2025 Nasdaq indexes. Lifecore's inclusion in the Nasdaq Biotech Index will be effective prior to market open on Monday, December 22, 2025. | GlobeNewsWire | 2025-12-18 07:00:00 |
| Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer | Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product | GlobeNewsWire | 2025-12-17 07:00:00 |
| Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference | CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 44th Annual J.P. | GlobeNewsWire | 2025-12-16 07:00:00 |
| Halper Sadeh LLC Encourages Lifecore Biomedical, Inc. Shareholders to Contact the Firm to Discuss Their Rights | NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary duties to shareholders. If you currently own Lifecore stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about. | Business Wire | 2025-12-07 14:49:00 |
| Lifecore Biomedical to Participate in Upcoming Investor Conferences | CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in two upcoming investor conferences. Details regarding Lifecore's participation are as follows: | GlobeNewsWire | 2025-11-11 16:05:00 |
| Lifecore Biomedical, Inc. (LFCR) Q3 2025 Earnings Call Transcript | Lifecore Biomedical, Inc. ( LFCR ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Paul Josephs - President, CEO & Director Ryan Lake - Executive VP & CFO Conference Call Participants Stephanie Diaz - Vida Strategic Partners, Inc. Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Hannah Hefley - Stephens Inc., Research Division Lucas Baranowski - KeyBanc Capital Markets Inc., Research Division Christine Rains - William Blair & Company L.L.C., Research Division Presentation Stephanie Diaz Vida Strategic Partners, Inc. Good afternoon, and thank you for joining us today to discuss Lifecore Biomedical's Third Quarter 2025 Earnings results for the 3 months ended September 30, 2025. | Seeking Alpha | 2025-11-06 20:56:07 |
| Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update | -- Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025 , Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Customers -- -- Continued Improvements in Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced its financial results for the three months ended September 30, 2025. | GlobeNewsWire | 2025-11-06 16:05:00 |
| Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025 | CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the three months ended September 30, 2025, on Thursday, November 6, 2025, after market close. | GlobeNewsWire | 2025-10-30 16:05:00 |
| Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company | Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product | GlobeNewsWire | 2025-10-29 07:00:00 |
| Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market | CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract development and manufacturing, today announced the signing of a collaboration agreement aimed at providing an integrated, end-to-end solution for peptide-based pharmaceutical customers in the U.S. | GlobeNewsWire | 2025-10-28 07:00:00 |
| Lifecore Biomedical to Participate at Upcoming Industry Conferences and Events | CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at three upcoming industry events. Details of the company's activities at these events are as follows: | GlobeNewsWire | 2025-10-13 07:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2025-11-17 | 2025-11-17 | View Filing |
| 10-Q | 2025-11-06 | 2025-11-06 | View Filing |
| 8-K | 2025-11-06 | 2025-11-06 | View Filing |
| 8-K | 2025-10-31 | 2025-10-31 | View Filing |
| SC 13G/A | 2025-10-17 | 2025-10-17 | View Filing |
| EFFECT | 2025-10-01 | 2025-10-01 | View Filing |
| 424B3 | 2025-09-30 | 2025-09-30 | View Filing |
| 8-K | 2025-09-26 | 2025-09-26 | View Filing |
| S-3 | 2025-09-23 | 2025-09-22 | View Filing |
| DEF 14A | 2025-09-18 | 2025-09-18 | View Filing |
| 4 | 2025-09-04 | 2025-09-04 | View Filing |
| 8-K | 2025-08-18 | 2025-08-18 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| S-8 | 2025-08-07 | 2025-08-07 | View Filing |
| 10-K | 2025-08-07 | 2025-08-07 | View Filing |
| 8-K | 2025-08-07 | 2025-08-07 | View Filing |
| 8-K | 2025-07-18 | 2025-07-18 | View Filing |
| SC 13G | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-07-17 | 2025-07-17 | View Filing |
| 4 | 2025-07-10 | 2025-07-10 | View Filing |
| 4 | 2025-07-10 | 2025-07-10 | View Filing |
| 4 | 2025-07-10 | 2025-07-10 | View Filing |
| SC 13D/A | 2025-05-29 | 2025-05-29 | View Filing |
| 4 | 2025-05-28 | 2025-05-28 | View Filing |
| 4 | 2025-05-22 | 2025-05-22 | View Filing |
| 4 | 2025-05-16 | 2025-05-16 | View Filing |
| 4 | 2025-05-12 | 2025-05-12 | View Filing |
| 4 | 2025-05-07 | 2025-05-07 | View Filing |
| 8-K | 2025-04-16 | 2025-04-16 | View Filing |
| 4 | 2025-04-16 | 2025-04-16 | View Filing |
| 3 | 2025-04-16 | 2025-04-16 | View Filing |
| 8-K | 2025-04-10 | 2025-04-10 | View Filing |
| 10-Q | 2025-04-03 | 2025-04-03 | View Filing |
| 8-K | 2025-04-03 | 2025-04-03 | View Filing |
| DEF 14A | 2025-02-27 | 2025-02-27 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-05 | 2025-02-05 | View Filing |
| PRE 14A | 2025-01-21 | 2025-01-21 | View Filing |
| DEFA14A | 2025-01-17 | 2025-01-17 | View Filing |
| 8-K | 2025-01-17 | 2025-01-17 | View Filing |
| 4 | 2025-01-08 | 2025-01-08 | View Filing |
| 8-K | 2025-01-07 | 2025-01-07 | View Filing |
| 10-Q | 2025-01-02 | 2025-01-02 | View Filing |
| 8-K | 2025-01-02 | 2025-01-02 | View Filing |
| SC 13D/A | 2024-12-26 | 2024-12-26 | View Filing |
| 4 | 2024-12-10 | 2024-12-10 | View Filing |
| 4 | 2024-12-10 | 2024-12-10 | View Filing |
| 8-K | 2024-11-26 | 2024-11-26 | View Filing |
| 8-K | 2024-11-21 | 2024-11-21 | View Filing |
| 8-K | 2024-11-08 | 2024-11-08 | View Filing |
| 4 | 2024-10-29 | 2024-10-29 | View Filing |
| 424B3 | 2024-10-23 | 2024-10-23 | View Filing |
| EFFECT | 2024-10-23 | 2024-10-23 | View Filing |
| EFFECT | 2024-10-16 | 2024-10-16 | View Filing |
| S-8 | 2024-10-10 | 2024-10-10 | View Filing |
| S-8 | 2024-10-10 | 2024-10-10 | View Filing |
| S-1 | 2024-10-10 | 2024-10-10 | View Filing |
| POS AM | 2024-10-10 | 2024-10-10 | View Filing |
| 4 | 2024-10-07 | 2024-10-07 | View Filing |
| 4 | 2024-10-07 | 2024-10-07 | View Filing |
| SC 13D/A | 2024-10-07 | 2024-10-07 | View Filing |
| 10-Q | 2024-10-04 | 2024-10-04 | View Filing |
| 8-K | 2024-10-04 | 2024-10-04 | View Filing |
| DEF 14A | 2024-09-23 | 2024-09-23 | View Filing |
| 8-K | 2024-09-23 | 2024-09-23 | View Filing |
| 4/A | 2024-09-16 | 2024-09-16 | View Filing |
| 8-K | 2024-09-12 | 2024-09-12 | View Filing |
| 4 | 2024-09-05 | 2024-09-05 | View Filing |
| 3 | 2024-09-05 | 2024-09-05 | View Filing |
| 8-K | 2024-08-29 | 2024-08-29 | View Filing |
| 8-K | 2024-08-26 | 2024-08-26 | View Filing |
| 10-K | 2024-08-26 | 2024-08-26 | View Filing |
| 4 | 2024-08-22 | 2024-08-22 | View Filing |
| 3 | 2024-08-22 | 2024-08-22 | View Filing |
| 4 | 2024-08-21 | 2024-08-21 | View Filing |
| 4 | 2024-08-21 | 2024-08-21 | View Filing |
| 4 | 2024-08-21 | 2024-08-21 | View Filing |
| 3 | 2024-08-21 | 2024-08-21 | View Filing |
| 3 | 2024-08-21 | 2024-08-21 | View Filing |
| 3 | 2024-08-21 | 2024-08-21 | View Filing |
| 8-K | 2024-08-21 | 2024-08-21 | View Filing |
| NT 10-K | 2024-08-12 | 2024-08-12 | View Filing |
| 10-Q | 2024-08-09 | 2024-08-09 | View Filing |
| 10-Q | 2024-08-09 | 2024-08-09 | View Filing |
| 10-Q | 2024-08-09 | 2024-08-09 | View Filing |
| DEFA14A | 2024-08-09 | 2024-08-09 | View Filing |
| 8-K | 2024-07-24 | 2024-07-24 | View Filing |
| DEF 14A | 2024-07-19 | 2024-07-19 | View Filing |
| 8-K | 2024-07-12 | 2024-07-12 | View Filing |
| 4 | 2024-07-10 | 2024-07-10 | View Filing |
| 4 | 2024-07-10 | 2024-07-10 | View Filing |
| 4 | 2024-07-10 | 2024-07-10 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Swarm Intelligence Strategy | 37.66% | 1 | 616 | 0.04 | 0.08 | 25.62 |
| Keltner Channel Strategy | 27.09% | 0.99 | 160 | 0.04 | 0.14 | 15.05 |
| Larry Williams PercentR Strategy | 24.31% | 0.99 | 167 | 0.05 | 0.08 | 12.27 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxx |